Denali Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
DNLI$20.33+1.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Financial Statements and Supplementary Data
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
| Denali Therapeutics Inc. | |
|---|---|
| Index to Consolidated Financial Statements | |
| Page | |
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 135 |
| Consolidated Balance Sheets | 137 |
| Consolidated Statements of Operations and Comprehensive Loss | 138 |
| Consolidated Statements of Stockholders' Equity | 139 |
| Consolidated Statements of Cash Flows | 140 |
| Notes to Consolidated Financial Statements | 141 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.